Related Experiment Video
Updated: Sep 16, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
MYC Regulates a DNA Repair Gene Expression Program in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
James R Evans1,2, Jing Wang3,4, Cinthia N Reed1,2
1Department of Biology, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Background/Objectives:
SCCOHT is an aggressive and often fatal cancer that belongs to the ~20% of cancers defined by mutations to subunits of the SWI/SNF chromatin remodeling complex. In SCCOHT, mutations to the SMARCA4 gene, which encodes the SWI/SNF ATPase BRG1, are sufficient to impair SWI/SNF function. This single genetic lesion leads to a cascade of events that promote tumorigenesis, some of which may involve the intersection of SWI/SNF with oncogenic pathways such as those regulated by the MYC oncogene. In SCCOHT tumors and other cancers marked by SWI/SNF subunit mutation, MYC target genes are recurrently activated, pointing to a relationship between SWI/SNF and MYC that has yet to be fully explored.
Methods:
In this study, we investigate the contribution of MYC to SCCOHT biology by performing a combination of chromatin binding and transcriptome assays in genetically engineered SCCOHT cell lines, with subsequent validation using patient tumor expression data.
Results:
We find that MYC binds to thousands of active promoters in the BIN-67 SCCOHT cell line and that the depletion of MYC results in a broad range of gene expression changes with a notable effect on the expression of genes related to DNA repair. We uncover an MYC-regulated DNA repair gene expression program in BIN-67 cells that is antagonized by BRG1 reintroduction. Finally, we identify a DNA repair gene signature that is upregulated in SCCOHT tumors and in tumors defined by loss of the SWI/SNF subunit SNF5.
Conclusions:
Collectively, these data implicate MYC as a robust regulator of DNA repair gene expression in SCCOHT and lay a foundation for future studies focused on interrogating the relationship between BRG1 and MYC.
Insights
MYC drives DNA repair gene expression in small cell ovarian cancer (SCCOHT), a cancer linked to SWI/SNF mutations. Restoring BRG1 counteracts this MYC program, suggesting therapeutic targets for SCCOHT.
Area of Science:
- Oncology
- Cancer Genomics
- Chromatin Remodeling
Background:
- Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive cancer often driven by mutations in SWI/SNF chromatin remodeling complex genes, such as SMARCA4.
- SMARCA4 mutations impair SWI/SNF function, potentially impacting oncogenic pathways like MYC, which is frequently activated in SWI/SNF-mutant cancers.
Purpose of the Study:
- To investigate the role of MYC in SCCOHT biology.
- To explore the interplay between SWI/SNF (specifically BRG1) and MYC in regulating gene expression and DNA repair in SCCOHT.
Main Methods:
- Utilized genetically engineered SCCOHT cell lines for chromatin binding and transcriptome assays.
- Performed validation using patient tumor expression data.
- Investigated the effects of MYC depletion and BRG1 reintroduction on gene expression.
Main Results:
- MYC binds to numerous active promoters in SCCOHT cells.
- MYC depletion broadly alters gene expression, particularly affecting DNA repair genes.
- An MYC-driven DNA repair gene expression program was identified, which is inhibited by BRG1.
- A DNA repair gene signature is upregulated in SCCOHT tumors and SWI/SNF-deficient tumors.
Conclusions:
- MYC is a significant regulator of DNA repair gene expression in SCCOHT.
- These findings highlight a potential functional relationship between BRG1 and MYC in SCCOHT tumorigenesis.
- The study provides a basis for further research into BRG1-MYC interactions and therapeutic strategies for SCCOHT.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
Epigenetic Regulation
X-chromosome...
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...